Kidney Disease News
-
Lowering sodium intake, a drumbeat of doctors’ efforts to improve patient health, may have the opposite effect if taken to the extreme, scientists said.
-
AbbVie Inc., the drugmaker split off from Abbott Laboratories this year, will fire its sales force for heart drugs as the medicines lose patent protection and face generic competition, according to a person familiar with the matter.
-
Genzyme Corp. and Bone Care International Inc. won a U.S. judge’s ruling that their patent for the kidney disease drug Hectorol is valid and enforceable.
-
The first man on the moon, the first U.S. woman in space and the first black Federal Reserve member were among the notable deaths in 2012.
-
Merck & Co.’s blockbuster cholesterol drug Vytorin won the backing of an advisory panel to prevent heart attack and stroke in some patients with kidney disease.
-
Merck & Co., the second-biggest U.S. drugmaker, said cholesterol treatments Vytorin and Zetia failed to win approval to prevent heart attacks and strokes in patients with chronic kidney disease.
-
An experimental drug from Abbott Laboratories and Reata Pharmaceuticals Inc. reversed the decline of kidney function in diabetics in a study that doctors say may lead to a new way of treating chronic kidney disease.
-
Hospitalizations related to chronic kidney disease are increasing in Australia, spurred by rising rates of Type 2 diabetes, according to a report released today by the Australian Institute of Health and Welfare.
-
Johnson & Johnson’s pursuit of profit led it to sell a defective metal-on-metal hip that failed faster than any similar device, a lawyer argued at the first of 10,750 lawsuits over the recalled implant to go to trial.
-
Diabetic patients with chronic kidney disease are more likely to suffer heart complications or die if they need higher doses of Amgen Inc. ’s Aranesp to reach current treatment goals, researchers said.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page